Fulgent Genetics, Inc. (FLGT): Nasdaq/NYSE listing notice — Fulgent Genetics receives Nasdaq non-compliance letter for audit committee shortage; cure period to Oct 2023

Fulgent Genetics, Inc.

Received Nasdaq letter Nov 18, 2022: audit committee has 2 independent directors instead of required 3.
Cure period expires at earlier of next annual meeting or Oct 31, 2023; if meeting before May 1, 2023, then May 1, 2023.
Company plans to appoint an additional independent director to regain compliance.
No immediate impact on listing or trading of FLGT common stock on Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Fulgent Genetics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605

Exact text from the filing

November 18, 2022, Fulgent Genetics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to

View on SEC.gov

Browse all listing & compliance notices →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-025666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.